IQVIA (NYSE:IQV) Cut to “Neutral” at BTIG Research

BTIG Research lowered shares of IQVIA (NYSE:IQV) from a buy rating to a neutral rating in a report released on Monday, Marketbeat Ratings reports.

A number of other research firms have also issued reports on IQV. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Stock Up 2.5 %

IQVIA stock opened at $205.12 on Monday. The firm has a market cap of $37.23 billion, a price-to-earnings ratio of 26.92, a P/E/G ratio of 2.15 and a beta of 1.48. The firm has a fifty day moving average price of $200.29 and a two-hundred day moving average price of $219.97. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IQV. Smith Group Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. grew its stake in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Fifth Third Bancorp raised its position in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.